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Introduction
Liquid chromatography - high resolution mass spectrometry (LC-
HRMS) analyses now rival LC-MS/MS techniques in terms of both 
compound specificity and quantitative detection capabilities [1-4]. LC-
MS/MS techniques depend on the predetermination of the fragments 
ions from a precursor ion characteristic of the target analyte. For the 
drug captopril [5], for example, the precursor ion would be MH+ at 
m/z 218.0 and the previously identified fragment ions are m/z 172.0 and 
116.0. These are the values applied to MS1 and MS2 in an LC-MS/MS 
(triple quadrupole) instrument in order to detect captopril during the 
elution of a sample. In the HRMS (Time of Flight MS) instrument all 
ions are recorded during sample elution and this data is then scanned 
for the presence of ions at m/z 218.0845 characteristic of captopril. In 
analyses of this type the ToF MS measures m/z values typically to an 
accuracy of 10 parts per million in mass. This approach means that 
the LC-HRMS results can be re-interrogated for other analytes at a 
later date without the need to re-run samples. In this paper LC-HRMS 
analyses of Dried Blood Spot (DBS) samples are used to assess patient 
adherence to prescribed medication.  
Adherence to medication refers to whether a patient takes their 
medication exactly as prescribed by the clinician or doctor [6], for 
example, three times a day after meals or one to be taken at night. 
Furthermore the complete course of medication should be taken as 
required by the prescription. Despite what might be expected levels of 
adherence to medication are NOT good. Examples of poor adherence 
include ~40% for people with heart disease in the US and UK, ~ 50% for 
patients with breast cancer and as low as ~15% for some haematological 
cancers [7]. It is not surprising therefore that there are some 320,000 
unnecessary deaths in the EU and USA annually resulting from 
improper use of medicines [8]. Other consequences of poor adherence 
to medication include medicine wastage and extended patient illness 
resulting in additional hospital and healthcare costs [9]. Clearly 
therefore medication adherence must be regarded as one of the most 
understated problems for the healthcare systems worldwide. In 2003 
the World Health Organization suggested that ‘improving medication 
adherence would provide more benefits to people worldwide than the 
development of new medicines’ [10]. In the UK the medicines costs, 
within the NHS, constitute the second largest identifiable unit after staff 
costs [11]. Improved adherence to medication offers an opportunity to 
reduce or at least optimize some of the £11 billion current costs to the 
NHS. 
Direct analysis of patient biofluids (blood, urine or saliva) 
provides the only unambiguous assessment of adherence to prescribed 
medication. Other recognized methods of assessment can produce 
misleading information, for example, tablets are collected but may not 
be taken, there are optimistic answers to questionnaires and patients 
may mislead clinicians [12]. Whilst both urine and saliva analyses can 
be used to show adherence the relationship between both the time of 
ingestion and the dose taken cannot readily be established. The work 
reported here demonstrates that the analyses of Dried Blood Spots 
(DBS) samples, collected from a minimally invasive finger prick, can 
provide a quantitative assessment of adherence to medication. The 
advantages of DBS based methods coupled with improved analytical 
instrumental capability has led to a surge in the use of this sampling 
methodology for various applications [13,14]. 
Experimental 
Target cardiovascular (CV) medication 
The selection of specific cardiovascular medication was informed by 
discussion with practicing clinicians and a survey of drug prescribing 
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Abstract
Research suggests that ~60% of patients prescribed cardiovascular drugs do not take their medication correctly. 
The analysis of dried blood samples (DBS) by liquid chromatography-high resolution mass spectrometry (LC-HRMS) 
for assessing medication adherence to candidate therapeutic drugs used in cardiovascular therapy was investigated. 
Specificity using this analytical method was based on the measurement at the accurate mass to charge ratio of the 
target analyte. To evaluate the method 8mm discs were punched from each DBS and extracted followed by subjecting 
to LC-HRMS analysis. Trials on 6 commonly UK used cardiovascular drugs are reported demonstrating the ability 
of the system to detect the target analytes during the 24 hour repeat prescription cycle. Samples from volunteers 
with confirmed adherence were used to validate the response from the system as were samples from volunteers 
receiving no medication. No false positives were observed and adherence assessment for bisoprolol, ramipril, 
amlodipine, valsartan, doxasozin and simvastatin was demonstrated using the LC-HRMS method. Furthermore 
examples of incorrect adherence were identified. 
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in the UK. The medicines identified as frequently prescribed CV drugs 
in the UK and selected for this study were: 
• Bisoprolol  beta blocker 
• Ramipril                    ace inhibitor 
• Simvastatin  statin 
• Amlodipine  calcium channel blocker
• Doxazosin  alpha blocker 
• Valsartan  angiotensin receptor blocker. 
Table 1 details the relevant pharmacokinetic (PK) information 
which will influence the detection capabilities required for this 
investigation. The aim of this work was to investigate if the presence 
of specified target drugs can be confirmed in blood samples from 
individual volunteers and therefore the ranges in the responses from 
different volunteer/drug combinations is more important than a mean 
value. Specifically therefore the worst case scenario, i.e. the lowest 
likely drug concentration in the DBS sample, must be considered. This 
will occur for a combination of low bioavailability, low dose, rapid 
elimination (short thalf) with a low Cmax developed in the shortest time 
(tmax). In this respect simvastatin should pose the major challenge. The 
other major factor affecting the level of drug to be detected was the time 
delay between the patient taking the medication and the subsequent 
provision of the blood spot sample. 
The data in (Table 1) shows the drug concentration in blood rising 
to a maximum (Cmax) usually after a short time (tmax) and then decreasing 
exponentially at a rate governed by thalf. This data is usually derived 
from experiments based on a single dose given to healthy volunteers. 
For long-term adherent volunteers a ‘steady state’ condition develops 
in which the initial rise in concentration is less marked and the rate 
of decrease is reduced. Under adherence conditions the steady state 
level, of the drug in blood, is the minimum level of drug available for 
detection. An indication of patient non-adherence will be derived from 
a combination of no signal above the instrument noise level and the 
passage of at least 5 half-lives abstinence. 
Volunteer samples 
In the initial phase of this investigation two sets of volunteers were 
selected from informed colleagues: 
• A group who routinely took one or more of the target medicines 
• A group who were prescribed none of the target medicines. 
 The volunteers in the first group, provided blood samples at 
specified times after taking known medication in order to provide 
controlled tests of the detection system. Analysis of DBS samples 
from the second group, volunteers known to take none of the target 
drugs, was used to provide baseline reference data for the trial samples. 
Replicate (n=5) ~30 µl volume blood spot samples were collected on 
Whatmann 903 sample paper either in the laboratory or by volunteer 
self-collection at home. The delay time between taking the prescribed 
medication and DBS sample collection was noted. After collection the 
samples were allowed to dry under ambient conditions for a minimum 
of 2 hours and were then sealed into plastic bags containing a dessicant. 
Self-collection at home was seen as a move towards cost saving versus 
conventional liquid blood sample collection. Volunteers willing to try 
this approach attended a laboratory training session. 
Chemicals and materials 
Acetonitrile, methanol and water of LC-MS grade were purchased 
from Sigma-Aldrich (Poole, UK). The active pharmaceutical ingredients 
(API) Atenolol (R-(+), 99%), bisoprolol hemifumarate salt, ramipril, 
valsartan, amlodipine besilate, simvastatin and doxazosin mesilate 
were also purchased from Sigma-Aldrich (Poole, UK). Formic acid, 
auto-sampler vials with 250 µl inserts and vial caps were purchased 
from Agilent Technologies (Cheshire, UK). Specimen collection 
paper type 903, micro-centrifuge tubes (1.5 ml), volumetric pipettes, 
pipette tips and polyethylene bags were obtained from Fisher Scientific 
(Loughborough, UK). An 8 mm diameter punch was obtained from 
Maun Industries Ltd. (Nottingham, UK). Lithium heparin coated 
blood collection tubes were purchased from International Scientifique 
Supplies Ltd. (Bradford, UK). Fresh blank blood was obtained from 
informed volunteers in line with De Montfort University Ethics 
Protocols. 
Sample analysis 
The preparation of standard solutions and spiked blood spot 
samples to produce calibration data for quantitative determinations 
has been detailed elsewhere [2] and is not duplicated here. An 8 mm 
disc was punched from the centre of the DBS sample and transferred 
to a 1.5 ml micro-centrifuge tube. A 150 µl of extraction solvent 
consisting of methanol/water (70:30, v/v) plus the internal standard 
(20 ng/ml) was added to this. Sample tubes were then vortexed for 1 
min and sonicated for 30 min. They were then centrifuged for 10 min 
at 13.2 x g and each extract was transferred to an auto-sampler vial for 
analysis by LC-HRMS. 
The LC-HRMS system consisted of an Agilent 1290 UPLC coupled 
to an Agilent 6530 QTOF mass spectrometer, used in the TOF only 
mode. The target drugs were analysed on an Zorbax Eclipse C18 rapid 
resolution HD column (Agilent Technologies, Cheshire, UK, 100 mm 
x 2.1 mm i.d., 1.8 µm particle pore size) which was preceded by a 0.3 
µm inline filter (Agilent Technologies, Cheshire, UK). The column 
oven temperature was set to 40°C. Sample injection volume was 20 µl. 
The mobile phase consisted of water containing 0.2% v/v formic acid 
(eluent A) and acetonitrile containing 0.2% v/v formic acid (eluent B) 
and was delivered at 0.6 ml/min with gradient elution. The mobile phase 
was initiated at 5% B and maintained for 0.5 min before increasing to 
20% B and then to 95% B by 1.5 min and held until 3.0 min before 
returning to 5% B. The gradient elution programme was then held 
for 1.5 min to re-equilibrate the column prior to the next injection.
The mass spectrometer was operated in the electrospray positive ion 
mode. The MS source and chamber conditions were optimised to give 
maximum analyte signal intensities as follows: Fragmentor voltage: 
165V; Skimmer: 65V; Gas Temperature: 350°C; Dry Gas: 10 l/min; 
Nebuliser: 50.0 psig; Sheath Gas Temperature: 400°C; Sheath Gas Flow: 
12 l/min. Mass Range: 100-1000 m/z; Recording Rate: 1 Hz. HRMS lock 
reference masses: 121.0508 m/z and 922.00987 m/z. Data acquisition 
was controlled by the Mass Hunter Workstation Software for TOF/Q-
Drug Dose range/mg Cmax /ng/ml Tmax/h Thalf/h
Bisoprolol [14] 2.5/5/10* 37-87 1.5-4 5-16
Ramipril [15] 2.5/5*/10 11-31 1-4 4-6
Amlodipine [16-18] 5*/10 5-7 5 5-8 35-50
Valsartan [19] 40/80/160* 879-3874 2-8 3.5-14
Doxasozin [20] 1/2/4/8*/6 67(17.6) 2.7-5 20.5 (6.1)
Simvastatin [21] 10/20/40* 5-40 2-3 1.3-2.7
Atenolol [14] 25/50* 159-377 1.5-6.0 4-11
Note: * Indicates dose taken for the data cited 
Table 1: Pharmacokinetic data for frequently prescribed cardiovascular drugs.
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TOF version B.04.00 (Agilent Technologies) and the acquired data 
was processed using Qualitative Analysis B.04.00 and Quantitative 
Analysis B.04.00 software (Agilent Technologies). External calibration 
of the TOF mass spectrometer was performed daily prior to starting 
the analysis. 
Validation 
A validation of this approach, following international guidelines, 
including data on selectivity, linearity, sensitivity, intra and inter-assay 
accuracy and precision has already been published [2]. 
Results and Discussion 
Selectivity 
Before any analyses could be undertaken it was necessary to 
determine the accurate masses of the target analytes and internal 
standard. Standard mass spectra in the full scan range 100-1000 m/z 
were obtained by injection of a multicomponent standard solution 
of the target drugs and the internal standard (20 ng/ml) in a mixture 
of methanol and water (70:30, v/v). The most intense ions under the 
chosen operating conditions were:
Drug   m/z           Species
Bisoprolol 326.2326           MH+
Ramipril 417.2384           MH+
Simvastatin  441.2611           MNa+
Amlodipine  431.1344           MNa+
Doxazosin 452.1928          MH+
Valsartan  436.2343         MH+
Atenolol (IS)  267.1703          MH+
Figure 1 shows the Extracted Ion Chromatograms (EICs) for these 
compounds using the appropriate accurate masses. These traces show 
that there were no interferences at the same retention time of each of 
the drugs which confirmed the good selectivity of the method. 
Volunteer samples 
To date a total of 488 samples of different combinations of 
volunteer/ target drug/time delay after dosing have been received from 
the volunteers taking medication including 40 samples from volunteers 
not prescribed any of the medicines investigated in this project. 
Analytical investigations routinely involve blank samples, baseline 
samples, calibration samples and the test samples. In this investigation 
blank samples were those provided by the volunteers known not to be 
taking any of the subject medicines. Baseline samples were obtained 
from volunteers immediately prior to them taking the due dose of 
medication. These samples corresponded to delays of at least 24 hours 
and demonstrating a detection capability at this level eliminates the 
possibility of reporting false negatives. A false negative output would 
occur if the system was unable to detect the real levels of the target drug 
present for an adherent volunteer (Figure 1).
Sample Quality: In order to provide useable data the blood 
sample must be uniform and of sufficient size to provide an 8mm 
diameter punched disc. All the laboratory collected samples met 
these requirements but 26 of 135 DBS samples collected at home were 
unsatisfactory. The spots on the unsatisfactory samples were either too 







m/z 326.2326 BISOPROLOL 
m/z 417.2384 RAMIPRIL 
m/z 441.2611 SIMVASTATIN 
m/z 431.1344 AMLODIPINE 
m/z 452.1928 DOXAZOSIN 
m/z 436.2343 VALSARTAN 
Figure 1: Representative LC-HRMS extracted ion chromatographs of the 
candidate APIs. 
represented a 19% failure rate for home sample collection. 
Sample time delay distribution: As might be expected, assuming 
most volunteers take their medication in the morning, the majority of 
the samples were collected within 12 hours of the dose being taken. 
More than 60% of the samples collected were within this timeframe 
and 26% had delay times between 12 and 18 hours. The delay time 
for simvastatin medication, taken at night, was either less than 4 
hours (50% of samples) or in excess of 16 hours (40% of samples) 
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corresponding to an overnight delay period. Periods in excess of 24 
hours were derived from judicious delays in taking the following dose. 
These results are summarized in Table 2. The total success of this phase 
of the investigation is testament to both the resolute adherence of the 
volunteers and to the performance of the system under this mode 
of operation. Inspection of the data for periods of >24 hours would 
suggest that whilst ions appropriate to simvastatin were detectable the 
levels seen would have been below the limits of quantification. 
Qualitative assessment of adherence 
All data was processed as the ratio of the peak area for the 
particular accurate mass divided by the peak area for the internal 
standard from the same sample extract. This approach was designed 
to reduce variations in the very low levels detected, resulting from 
minor differences in extraction efficiency and the analytical conditions. 
The baseline samples, i.e. those with a delay between 24 and 25 hours 
all showed a detectable signal for all the relevant target API for those 
volunteers who were known to be taking the specified medicines. This 
would be expected for regular medicine users who would develop a 
‘steady state’ level of the target drug in the blood. By contrast analysis 
of the samples from volunteers not taking any of the medicines (blank 
samples) produced no signal greater than the noise level at the retention 
times identified to be of interest. This observation confirms both the 
performance of the approach i.e. identifying absence of the target drugs 
and also that there were no other species present that could lead to 
an interfering signal. All of the samples from the control adherents to 
medication showed the presence of the expected target drugs which 
may either confirm good adherence or that knowing a test is coming 
will ensure the appropriate action, taking the medicine, occurs. 
Quantitative detection of the target cardiovascular drugs 
The quantitative work that has been carried out has been reported 
elsewhere [2] and has been validated in line with International guide 
lines on Bioanalytical method validation as summarized below: 
• Specificity-good for all the APIs investigated 
• Variation in accuracy and precision less than 15% 
• Linearity better than 0.991 
• Determination of LoD typically better than 1.0 ng/ml 
• Recovery range from ~98% for bisoprolol to ~40% for 
simvastatin 
• Matrix effects < 15% 
• Samples stable for 12 weeks. 
Quantitative information not only confirms that the medicine 
was taken but may also offer a further degree of assessment of precise 
adherence to prescription instructions. The concentrations of the target 
CV drugs determined in this work should relate to the data in Table 
1 which cites literature information on the maximum concentrations 
(Cmax /ng/ml) of these target drugs in the blood. The quantitative results 
were examined and in the measured concentrations were all of the same 
order as or below the Cmax levels from Table 1. In one set of replicates 
the level determined for the simvastatin concentration was 50% higher 
than the maximum expected. This high level raised a question since 
it is known that eating grapefruit products when taking simvastatin 
should be stopped. Under normal conditions the bioavailability of 
simvastatin is only ~ 5% with the remainder being metabolised before 
it can be absorbed into the blood. Grapefruit products compete with 
this metabolic pathway and consequently the levels of simvastatin in 
the blood can rise significantly [21]. When questioned, the volunteer 
explained that he took all his pills at the same time so he did not forget 
the simvastatin which should be taken at night. There was no evidence 
of grapefruit in the diet but one of his other CV drugs was known to 
have a similar effect on the metabolism of simvastatin. Here we have 
an example of the ability to identify non-adherence to prescription 
instructions, resulting in a medication error, which could only be 
identified from quantitative data. 
Conclusion
The advantages of using LC-HRMS analyses of the target 
CV drugs in DBS samples have been demonstrated for assessing 
medication adherence. The developed DBS based method correctly 
assessed adherence in a non-clinical setting and furthermore samples 
collected at home provided a viable but limited route to valuable data 
collection. Qualitative data provides a quick but limited assessment of 
adherence whereas quantitative data enabled a less obvious form of 
non-adherence to be identified. It is essential to ensure that the limit 
of detection for each target CV drug is below the steady state level for 
adherent volunteers. 
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